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Jefferson and colleagues say that nebulisation is the route of
administration for zanamivir.
1 However, prescribers should be
aware that the approved use of zanamivir in the United States
and European Union is by inhalation, not nebulisation.
2 3
The Food and Drug Administration recently issued a warning
against using the inhalation formulation in a solubilised form
fornebuliseddelivery,
4andlettershavebeensenttoprescribers
in the US proscribing the use of zanamivir by the nebulised
routebecauseofareporteddeathafteradministrationthisway.
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